Clovis Oncology shares were up by about 30% in trading after market close--driven by expectations for its rucaparib to treat advanced ovarian cancer, which was…

A new deal from Novartis outlicenses its Phase II-ready, anti-PCSK9 antibody for a couple of inflammatory indications that include sepsis.

Gilead and Galapagos have hit go on a Phase III trial program for their rheumatoid arthritis drug, filgotinib.

Microcap Tokai has had a summer to forget, but its woes got worse this week as it announced that it will stop enrollment in one trial and ax another as its…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…

PixarBio hopes to have an FDA-approved, non-addictive pain treatment that would offer a viable alternative to morphine by 2018. The company is reverse merging…

Regeneron Pharmaceuticals and the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) have…

Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…